BRPI0509209A - composto, métodos para contracepção, terapia de reposição hormonal, tratamento ou prevenção de doença neoplásica dependente de hormÈnios; tratamento de sangramento disfuncional ou da sìndrome de ovários policìsticos; sincronização do estro; tratamento da acne ou tratamento do hirsutismo, e para preparação do composto, composição farmacêutica, kit farmacêutico, e, uso de um composto - Google Patents

composto, métodos para contracepção, terapia de reposição hormonal, tratamento ou prevenção de doença neoplásica dependente de hormÈnios; tratamento de sangramento disfuncional ou da sìndrome de ovários policìsticos; sincronização do estro; tratamento da acne ou tratamento do hirsutismo, e para preparação do composto, composição farmacêutica, kit farmacêutico, e, uso de um composto

Info

Publication number
BRPI0509209A
BRPI0509209A BRPI0509209-4A BRPI0509209A BRPI0509209A BR PI0509209 A BRPI0509209 A BR PI0509209A BR PI0509209 A BRPI0509209 A BR PI0509209A BR PI0509209 A BRPI0509209 A BR PI0509209A
Authority
BR
Brazil
Prior art keywords
treatment
compound
contraception
hormone
prevention
Prior art date
Application number
BRPI0509209-4A
Other languages
English (en)
Inventor
Bogdan Kazimierz Wilk
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0509209A publication Critical patent/BRPI0509209A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Ink Jet (AREA)

Abstract

COMPOSTO, MéTODOS PARA CONTRACEPçãO, TERAPIA DE REPOSIçãO HORMONAL, TRATAMENTO OU PREVENçãO DE DOENçA NEOPLáSICA DEPENDENTE DE HORMÈNIOS; TRATAMENTO DE SAGRAMENTO DISFUNCIONAL OU DA SìNDROME DE OVáRIOS POLICìSTICOS; SINCRONIZAçãO DO ESTRO; TRATAMENTO DA ACNE OU TRATAMENTO DO HIRSUTISMO, E PARA PREPARAçãO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, KIT FARMACêUTICO, E, USO DE UM COMPOSTO Os compostos de tioamida e, especificamente, os compostos de tiomida pirrol, e sua preparação, são fornecidos. estes compostos de tiomida podem usados como moduladores do receptor da progesterona, na contracepção e no tratamento de doenças relacionadas à progesterona (fórmula I).
BRPI0509209-4A 2004-04-08 2005-04-07 composto, métodos para contracepção, terapia de reposição hormonal, tratamento ou prevenção de doença neoplásica dependente de hormÈnios; tratamento de sangramento disfuncional ou da sìndrome de ovários policìsticos; sincronização do estro; tratamento da acne ou tratamento do hirsutismo, e para preparação do composto, composição farmacêutica, kit farmacêutico, e, uso de um composto BRPI0509209A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56056904P 2004-04-08 2004-04-08
PCT/US2005/011757 WO2005100346A1 (en) 2004-04-08 2005-04-07 Thioamide derivatives as progesterone receptor modulators

Publications (1)

Publication Number Publication Date
BRPI0509209A true BRPI0509209A (pt) 2007-08-28

Family

ID=34965700

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509209-4A BRPI0509209A (pt) 2004-04-08 2005-04-07 composto, métodos para contracepção, terapia de reposição hormonal, tratamento ou prevenção de doença neoplásica dependente de hormÈnios; tratamento de sangramento disfuncional ou da sìndrome de ovários policìsticos; sincronização do estro; tratamento da acne ou tratamento do hirsutismo, e para preparação do composto, composição farmacêutica, kit farmacêutico, e, uso de um composto

Country Status (14)

Country Link
US (4) US7358246B2 (pt)
EP (1) EP1732921B1 (pt)
JP (1) JP4869221B2 (pt)
CN (1) CN100522960C (pt)
AT (1) ATE413398T1 (pt)
AU (1) AU2005233591B2 (pt)
BR (1) BRPI0509209A (pt)
CA (1) CA2561014C (pt)
DE (1) DE602005010840D1 (pt)
DK (1) DK1732921T3 (pt)
ES (1) ES2317223T3 (pt)
MX (1) MXPA06011696A (pt)
PL (1) PL1732921T3 (pt)
WO (1) WO2005100346A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4950027B2 (ja) * 2004-04-08 2012-06-13 ワイス・エルエルシー チオアミド不純物を最小限に抑えるための方法
EP1732921B1 (en) * 2004-04-08 2008-11-05 Wyeth Thioamide derivatives as progesterone receptor modulators
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
US20070093548A1 (en) * 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
US7618989B2 (en) * 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
US20090170823A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
CN107281215A (zh) * 2016-04-01 2017-10-24 复旦大学附属妇产科医院 硫化氢供体硫氢化钠在制药中的用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4295987A (en) 1979-12-26 1981-10-20 The Procter & Gamble Company Cross-linked sodium polyacrylate absorbent
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
AU608891B2 (en) 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
US5273752A (en) 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5124455A (en) 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
US5459151A (en) 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
US5854388A (en) 1993-06-24 1998-12-29 Washington State University Research Foundation Angiotensin IV peptides and receptor
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5756127A (en) 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
FI971385A0 (fi) 1997-04-04 1997-04-04 Bioxid Oy Biokompatibel komposition, metoder foer dess framstaellning samt anvaendning daerav
KR100732692B1 (ko) * 1999-05-04 2007-06-27 와이어쓰 프로게스테론 수용체 조절인자인 시클로티오카르바메이트유도체
AU767762B2 (en) * 1999-05-04 2003-11-20 Wyeth Thio-oxindole derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
HUP0202936A3 (en) 1999-08-10 2003-11-28 Smithkline Beecham Corp 1,4-substituted 4,4-diaryl cyclohexanes, pharmaceutical compositions containing them and their use
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
JP4716547B2 (ja) * 2000-08-10 2011-07-06 住友精化株式会社 ２−フェニルチアゾール類の製造方法
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
CA2485641C (en) * 2002-06-06 2010-12-14 Eisai Co., Ltd. Novel condensed imidazole derivatives
MXPA04012418A (es) 2002-06-25 2005-04-19 Wyeth Corp Uso de derivados de tio-oxindol en tratamiento de trastornos de la piel.
EP1531824A4 (en) 2002-06-25 2005-09-21 Wyeth Corp CYCLOTHIOCARBAMATE DERIVATIVES AS PR-MODULATORS AND THEIR USE IN THE TREATMENT OF SKIN DISEASES
JP2005535623A (ja) * 2002-06-25 2005-11-24 ワイス ホルモン関連症状の治療における、チオ−オキシインドール誘導体の使用
AU2003247608A1 (en) 2002-06-25 2004-01-06 Wyeth Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
JP4950027B2 (ja) * 2004-04-08 2012-06-13 ワイス・エルエルシー チオアミド不純物を最小限に抑えるための方法
EP1732921B1 (en) 2004-04-08 2008-11-05 Wyeth Thioamide derivatives as progesterone receptor modulators
JP4906711B2 (ja) 2004-04-08 2012-03-28 ワイス・エルエルシー ３−シクロペンチルオキシ−４−メトキシベンズアルデヒドの製造方法
BRPI0510260A (pt) 2004-04-27 2007-10-23 Wyeth Corp método para purificar um composto, e, kit farmacêutico

Also Published As

Publication number Publication date
US7659265B2 (en) 2010-02-09
PL1732921T3 (pl) 2009-04-30
DE602005010840D1 (de) 2008-12-18
EP1732921A1 (en) 2006-12-20
JP4869221B2 (ja) 2012-02-08
EP1732921B1 (en) 2008-11-05
US20080167299A1 (en) 2008-07-10
CN100522960C (zh) 2009-08-05
ATE413398T1 (de) 2008-11-15
CN1938299A (zh) 2007-03-28
US7358246B2 (en) 2008-04-15
WO2005100346A1 (en) 2005-10-27
US8168672B2 (en) 2012-05-01
US20050227971A1 (en) 2005-10-13
US20090143345A1 (en) 2009-06-04
DK1732921T3 (da) 2009-02-23
AU2005233591B2 (en) 2011-10-27
ES2317223T3 (es) 2009-04-16
JP2007532564A (ja) 2007-11-15
MXPA06011696A (es) 2006-12-14
CA2561014C (en) 2013-09-10
CA2561014A1 (en) 2005-10-27
US7511071B2 (en) 2009-03-31
US20100197645A1 (en) 2010-08-05
AU2005233591A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
BRPI0513141A (pt) composição para anel vaginal, e, processo de contracepção a longo prazo
NO20022292L (no) Nye topiske östrogenprogestogenpreparater med systemisk effekt
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
BR122012030846B8 (pt) composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e pelo menos um corticoesteróide, e, uso da mesma
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
CL2009001936A1 (es) Compuestos derivados de piridazina, inhibidores de 11beta-hsd1; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de la diabetes, obesidad, dislipidemia, trastornos de ingestion de comida e hipertension (divisional de solicitud 1720-2006).
BRPI0411335A (pt) método para preparar uma formulação de estradiol de liberação lenta, formulação farmacêutica, microesferas de estradiol e colesterol, método para efetuar contracepção e terapia de reposição hormonal simultáneas, e, kit
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
BG66075B1 (en) Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
CL2004001267A1 (es) Compuestos derivados de quinazolina, inhibidor de quinasa; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para preparar un medicamento para tratar trastornos proliferativos celulares tales como ateroesclerosis,
WO2008049516A3 (de) Transdermales therapeutisches system enthaltend norelgestromin zur kontrazeption und hormonsubstitution
IL176738A0 (en) Selective estrogen receptor modulators for the treatment of vasomotor symptoms
BR0312054A (pt) Uso de derivados de tio-oxindol na preparação de medicamentos úteis no tratamento de condições relacionadas com hormÈnio, e kit farmacêutico
GB0307777D0 (en) Conjugate compounds
SE0400346D0 (sv) Steroids for cancer treatment
AR044350A1 (es) Manguito y parche analgesico microencapsulado de uso topico para el tratamiento del dolor
SG152257A1 (en) Topical preparation containing ambroxol
EA200970376A1 (ru) Peg-илированный паратиреоидный гормон в качестве модулятора рецептора паратиреоидного гормона и его применение
DK1732921T3 (da) Thiomidderivater som progesteronreceptormodulatorer
NO20033555D0 (no) Sammensetning av östrogen og andre hormoner med askorbatlysin, prolin og andre stoffer
BRPI0507987A (pt) métodos e compostos moduladores receptor de glicocorticóide
NO20080440L (no) Ikke-steroide progesteronreseptormodulatorer
UA92500C2 (ru) Цианопирролсульфонамидные модуляторы прогестеронового рецептора и их применение
WO2003084521A3 (en) Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
WO2000059447A3 (fr) Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: WYETH LLC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.